Synonyms: Mulpleta® | S-888711 | S888711
lusutrombopag is an approved drug (Japan (2015), FDA (2018), EMA (2019))
Compound class:
Synthetic organic
Comment: Lusutrombopag is an orally bioavailable, nonpeptidyl, small molecule thrombopoietin (TPO) receptor agonist [3] that was developed by Shionogi in Japan. It was the second TPO receptor agonist to receive FDA approval in 2018 (avatrombopag was the first).
|
|
References |
1. FDA.
Lusutrombopag; FDA Approved Drug Products. Accessed on 01/08/2018. Modified on 01/08/2018. Drugs@FDA, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process |
2. Kim ES. (2016)
Lusutrombopag: First Global Approval. Drugs, 76 (1): 155-8. [PMID:26666417] |
3. Yoshida H, Yamada H, Nogami W, Dohi K, Kurino-Yamada T, Sugiyama K, Takahashi K, Gahara Y, Kitaura M, Hasegawa M et al.. (2018)
Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl. Exp Hematol, 59: 30-39.e2. [PMID:29274361] |